What to Know and Do if Your Partner Has Herpes

Herpes is one of the most common infections on the planet, and finding out your partner has it does not mean your relationship or your health is in danger. With a combination of daily antiviral medication and condom use, the annual risk of catching genital herpes from an infected partner drops to single-digit percentages, and most couples in this situation never transmit the virus at all. The science behind managing herpes in a relationship is more reassuring than the cultural stigma suggests, but there are real details worth understanding before you make decisions about sex, testing, and long-term planning.

HSV-1 and HSV-2 Are Not as Separate as You Think

When people say “herpes,” they could mean one of two closely related viruses. HSV-1 is traditionally linked to cold sores on the mouth, while HSV-2 is the classic genital herpes virus. That neat division has been breaking down for decades. In many high-income countries, HSV-1 has become the leading cause of first-episode genital herpes, especially among adolescents and young adults.¹ In Australia, for instance, the proportion of first genital herpes episodes caused by HSV-1 rose from 45% to 61% in women over a 14-year study period.²

This matters for you because if your partner tells you they have “herpes,” the first thing worth learning is which type they carry. The distinction affects how often outbreaks recur, how frequently the virus sheds between outbreaks, and what the practical risk looks like for you. Genital HSV-1 tends to recur far less often than genital HSV-2 and sheds less over time. A partner with genital HSV-1 poses a meaningfully lower ongoing transmission risk than one with HSV-2, though neither risk is zero.

How Herpes Spreads, Even Without Symptoms

The hardest thing for most people to accept about herpes is that it can spread when your partner looks and feels completely fine. The virus periodically reactivates and travels to the skin surface without producing visible sores. This is called asymptomatic shedding, and it accounts for a substantial share of new infections.

A large study that tracked daily genital swabs found that people with symptomatic HSV-2 shed virus on about 20% of days, while those who had never noticed symptoms still shed on roughly 10% of days.³ When virus was present during these symptom-free episodes, the amount of virus detected was similar regardless of whether the person had ever had noticeable outbreaks.³ In plain terms, even a partner who has never had a visible outbreak can shed enough virus to be infectious on any given day.

The good news is that shedding frequency declines over time. In the first year after a genital HSV-2 diagnosis, virus was detected on about a third of days. Between one and nine years out, that dropped to roughly one in five days, and after ten or more years it fell to about one in six.⁴ If your partner has had herpes for years, the baseline risk is already lower than it would be in the first months after infection.

Genital HSV-1 follows a similar trend but starts from a lower baseline. In the first few months after a primary genital HSV-1 infection, shedding occurred on about 17% of days. By a second sampling session later in the first year, shedding had already dropped to around 8.5% of days for those with primary infections.⁵ People whose genital HSV-1 was a nonprimary infection (meaning they already carried HSV-1 orally before it appeared genitally) shed even less frequently.

What You Can Do to Reduce Risk

Three tools make the biggest difference, and they stack on top of each other: antiviral medication, condoms, and outbreak awareness.

The landmark trial on antiviral suppression enrolled couples where one partner had genital HSV-2 and the other did not. The infected partner took either valacyclovir (500 mg daily) or a placebo. Among placebo partners, about 3.6% of susceptible partners acquired HSV-2 over the study period. Among valacyclovir partners, that dropped to 1.9%, cutting the overall acquisition rate roughly in half. When looking only at symptomatic infections rather than all lab-confirmed acquisitions, valacyclovir reduced the risk by 75%.⁶ That same trial found that viral shedding among partners taking valacyclovir dropped to about 3% of days, compared with nearly 11% on placebo.⁶

Condoms add another layer. A pooled analysis of six studies found that consistent condom use reduced HSV-2 acquisition by about 30% overall.⁷ That 30% figure may sound modest, and part of the reason is that herpes can spread through skin contact in areas a condom does not cover, such as the upper thighs and pubic region. But when researchers looked specifically at male-to-female transmission on a per-act basis, condom use reduced the risk by as much as 96%.⁸ The per-act protection from female to male was lower, around 65%, though that estimate did not reach strong statistical significance.⁸

The third strategy is straightforward: avoid genital contact during active outbreaks, including any prodromal tingling, itching, or burning your partner notices before sores appear. Outbreaks are the highest-risk period because viral loads are highest and open sores make transmission easier. Most couples already intuitively avoid sex during visible sores, but the prodromal symptoms that precede them by a day or two are equally important.

Combining all three measures, daily antivirals plus consistent condoms plus no sex during outbreaks, brings the annual transmission risk down substantially. No single study has tested the exact combination in a randomized trial, but the evidence for each layer is independent, and clinicians routinely counsel couples that using all three together makes transmission unlikely in any given year.

Direction of Transmission Matters

If you are a woman whose male partner has HSV-2, your risk of catching it is higher than the reverse scenario. In one well-known study of discordant couples, transmission occurred in about 17% of couples where the man was infected but only about 4% where the woman was.⁹ Several factors drive this. Men with HSV-2 tend to have about 20% more recurrences per year than women, which means more frequent shedding events.¹⁰ The anatomy of vaginal and vulvar tissue also appears to make women more susceptible to acquiring the virus during exposure. If you are a man whose female partner has herpes, the baseline risk is lower, but it is not negligible, and the same prevention strategies still apply.

Another subtlety: if you already carry HSV-1 (from childhood cold sores, for example), that may offer some partial protection against acquiring HSV-2. The same study found that prior HSV-1 infection appeared to reduce the risk of HSV-2 acquisition among women.⁹ This cross-protection is incomplete, but it means that your own HSV-1 status is part of the risk equation.

Getting Tested and Interpreting Results

One of the first things you may want to do is get tested yourself. You might already carry herpes without knowing it. Roughly half of new genital herpes infections produce no recognized symptoms, and many people with positive blood tests have never had a noticeable outbreak. But herpes blood tests deserve more scrutiny than most people give them, because false positives are a real and well-documented problem.

The standard commercially available test is an IgG antibody assay. These tests look for antibodies your immune system has produced against HSV-1 or HSV-2. They cannot tell you where on the body you are infected. The trouble is that the most widely used assays produce unreliable results at low-positive index values. In one study, about 40% of HSV-2 positive results with an index value between 1.1 and 2.9 turned out to be false positives when checked against a more reliable confirmatory method.¹¹ Results with index values of 3.0 or above were confirmed at much higher rates, around 79% in that same study.¹¹

A newer evaluation comparing three automated platforms confirmed that performance varies widely by manufacturer. One platform had a positive predictive value for HSV-2 of only about 69%, meaning nearly one in three positive results was wrong. Another platform achieved about 96%.¹² The risk of a false positive also increases if you already have HSV-1 antibodies, because some assays cross-react.¹³

If you get a low-positive HSV-2 result, ask about confirmatory testing. The gold standard confirmatory method has historically been Western blot, though availability is limited. For active sores, PCR swab testing is far more reliable than blood tests and is now considered the preferred diagnostic method for anyone with visible lesions.¹⁴ The practical takeaway: a positive blood test at a low index value is not a definitive answer, and a negative test does not always mean you are in the clear, since antibodies can take weeks to months to develop after a new infection.

Outbreaks, Triggers, and What Daily Life Actually Looks Like

If your partner has herpes, their experience of the virus probably looks less dramatic than you imagine. Many people have a noticeable first outbreak and then progressively milder and rarer recurrences. Some never have a visible outbreak at all. Recurrences can be triggered by stress, illness, hormonal shifts, or nutritional factors, all of which affect immune surveillance and allow the latent virus to reactivate periodically.¹⁵

Your partner may describe prodromal symptoms, a tingling, itching, or mild burning sensation in the genital area that signals a recurrence is coming before any sore appears. This is an important signal for both of you, because it means the virus is actively traveling to the skin surface and the risk of transmission is elevated. Some couples use these signals as their cue to pause sexual contact for a few days. Others rely on daily antivirals to suppress reactivation in the first place. Both approaches are reasonable, and many couples use a combination.

Over time, most people with HSV-2 notice that outbreaks become shorter, less painful, and less frequent. This tracks with the shedding data described earlier showing declining viral activity over the years. For people with genital HSV-1, outbreaks tend to be even rarer after the first year, and many have no clinical recurrences at all.

The Emotional Side and Why Disclosure Is Hard

The stigma around herpes far outstrips the medical reality of the infection. If your partner told you about their status, they did something difficult. Research on disclosure finds that fear of a negative partner reaction is the primary reason people with herpes avoid telling sexual partners at all.¹⁶ The decision to disclose is strongly tied to how committed the relationship feels and what the person expects your reaction will be.¹⁶ Stigma itself, not the medical symptoms, is the main barrier to honest conversations.¹⁷

How you respond matters enormously, both for your partner and for the relationship. People who disclose and receive a calm, supportive reaction tend to feel less psychological distress about their diagnosis going forward. Your partner is probably already dealing with some degree of shame or anxiety about the virus, and a reaction grounded in facts rather than fear goes a long way. If you need time to process the information, that is entirely fair. Ask your partner what type they have, when they were diagnosed, how often they experience outbreaks, and whether they take suppressive medication. These are practical questions, not invasive ones, and they give you the information you need to make informed choices.

Herpes, HIV, and Other Health Considerations

For most people in stable relationships, genital herpes is a manageable nuisance, not a serious health threat. But there is one significant medical implication worth knowing about: HSV-2 substantially increases susceptibility to HIV. A meta-analysis found that people with existing HSV-2 infection were about 2.7 times more likely to acquire HIV in general populations, and those with a recent HSV-2 infection faced an even higher risk, roughly 4.7 times.¹⁸ The mechanism is biological: active HSV-2 infection draws immune cells to the genital area that HIV targets, and can cause small breaks in the mucosal lining.¹⁹

This is primarily relevant if either you or your partner has other HIV risk factors, such as additional sexual partners or living in a region with high HIV prevalence. For monogamous couples where neither partner has HIV, the HSV-HIV interaction is not a concern in practice. But it is worth knowing if your circumstances change, and it is one more reason that suppressive antiviral therapy can be valuable: by reducing viral shedding and outbreak frequency, it likely lowers the elevated susceptibility as well.

Pregnancy and Planning Ahead

If you and your partner are thinking about having children, herpes adds a consideration but rarely a crisis. The greatest risk to a baby comes when a mother acquires a new genital herpes infection during the second half of pregnancy, because her immune system has not had time to produce antibodies that would cross the placenta and protect the newborn.²⁰ Neonatal herpes is rare but serious, and this scenario is the most dangerous version of it.

If your partner already had herpes before pregnancy, the risk to the baby is much lower. Years of infection mean your partner has antibodies that offer the baby passive protection, and shedding rates are lower. The standard precaution is to start suppressive antiviral therapy around 36 weeks of pregnancy and to deliver by cesarean section if active lesions are present at the time of labor.²⁰ If you are the partner without herpes and your female partner has the virus, these are decisions for her obstetrician. If you are the one with herpes and your female partner is not, the more pressing concern is making sure she does not acquire it during pregnancy, which brings the prevention strategies above into sharper focus.

Where Vaccine Research Stands

There is no approved vaccine for herpes yet, but the pipeline is more active now than at any point in the past. Several candidates have shown promising results in preclinical or early clinical work, including subunit vaccines, live-attenuated vaccines, and mRNA-based approaches.²¹ Some earlier candidates that looked encouraging in trials, such as GEN-003 and HerpV, stalled for various reasons and did not advance further.²¹

Herpes has been stubbornly difficult to vaccinate against because the virus hides in nerve cells in a latent state that the immune system cannot easily reach. A prophylactic vaccine that prevents new infections is the primary goal, but a therapeutic vaccine that reduces outbreaks and shedding in people who are already infected would also change the landscape for discordant couples. Neither is available today, but the range of approaches in development means the odds of eventually seeing an effective product are better than they were a decade ago. For now, the tools you have are the ones described above: antivirals, condoms, outbreak awareness, honest communication, and a clearer understanding of the actual risk than the stigma would suggest.